![](https://endpts.com/wp-content/uploads/2020/11/Giovanni-Caforio-Bristol-Myers-Squibb-tile-AP-scaled.jpg)
Giovanni Caforio, AP Images
Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer
Bristol Myers Squibb has worked overtime to hunt down an edge for its PD-(L)1 blocker Opdivo over rival Keytruda from Merck, including taking a bold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.